RNA Virus-Based Episomal Vector with a Fail-Safe Switch Facilitating Efficient Genetic Modification and Differentiation of iPSCs

Yumiko Komatsu,1,2 Dan Takeuchi,3 Tomoya Tokunaga,1 Hidetoshi Sakurai,4 Akiko Makino,1,5 Tomoyuki Honda,6 Yasuhiro Ikeda,7 and Keizo Tomonaga1,5,8

INTRODUCTION

Gene transfer technology that allows efficient and stable genetic modification of induced pluripotent stem cells (iPSCs) is a key component in developing a successful gene therapy. To date, various viral and non-viral technologies have been used for gene transfer into iPSCs. Although the use of integrating viral vectors offer stable transgene expression in iPSCs, the risks of insertional mutagenesis and oncogenesis are recognized as major safety concerns surrounding these vectors.1 Non-integrating viral vectors provide transient transgene expression in proliferating cells and, therefore, may not be suitable for long-term expression in iPSCs.2,3 Moreover, the efficiency of gene editing and off-target modifications represent major challenges in translating non-viral gene editing technologies for therapeutic applications.

A gene delivery system that allows efficient and safe stem cell modification is critical for next-generation stem cell therapies. An RNA virus-based episomal vector (REVec) is a gene transfer system developed based on Borna disease virus (BoDV), which facilitates persistent intranuclear RNA transgene delivery without integrating into the host genome. In this study, we analyzed susceptibility of human induced pluripotent stem cell (iPSC) lines from different somatic cell sources to REVec, along with commonly used viral vectors, and demonstrated highly efficient REVec transduction of iPSCs. Using REVec encoding myogenic transcription factor MyoD1, we further demonstrated potential application of the REVec system for inducing differentiation of iPSCs into skeletal muscle cells. Of note, treatment with a small molecule, T-705, completely eliminated REVec in persistently transduced cells. Development of an episomal vector system with an integrated safety switch would pave a new path for safe gene therapy applications. Another important feature for a safe gene delivery system is an ability to regulate transgene expression, or a suicide switch, as a fail-safe mechanism. Although several episomal vector systems are widely used in clinical applications, such as plasmid DNA, mini-circles, and adeno-associated virus (AAV) vectors,5 it has been highly challenging to accommodate a regulatable switch system or a self-degradation mechanism. For instance, there is no strategy currently available to completely eliminate AAV vector genomes in persistently transduced cells. Development of an episomal vector system with an integrated safety switch would pave a new path for safe gene therapy applications.

BoDV is a single-stranded, negative-strand RNA virus that persistently infects a wide range of cell types.6 BoDV is unique among the other RNA viruses for its ability to replicate inside the nucleus without causing overt cytopathic effects.7 BoDV persists as episomes whereby viral ribonucleoprotein (vRNP) interacts with core histones that form the chromatin.8 During cell division, vRNPs are segregated along with host chromosomes into each of the daughter cell nuclei. Since vRNP persists as episomes, integration is not required for its intranuclear infection.9

We have previously exploited the unique characteristics of BoDV and developed a viral vector system.10,11 We named this vector system an...
RNA virus-based episomal vector (REVec) system. In a follow-up study, we demonstrated that REVec achieves long-term transduction of human iPSCs without compromising its ability to differentiate into three embryonic germ layers. However, REVec transduction of mechanically dissociated iPSCs was relatively inefficient, and we were able to achieve up to 20% of iPSC transduction. In this study, we further explored potential applications of REVec for iPSC modification and transcription-factor-mediated induced differentiation. We demonstrated highly efficient (up to 80%) REVec transduction of single-cell-dissociated iPSCs with preserved pluripotency. REVec-mediated MyoD1 transfer induced iPSC differentiation into skeletal muscle cells. Importantly, treatment with T-705, a clinically approved small molecule, completely eliminated REVec genome in persistently transduced cells. Thus, our REVec system provides a unique genomic, modification-free, episomal gene delivery platform with a fail-safe switch-off system for stem cell modification.

RESULTS

Susceptibility of Human iPSC Lines to REVec

Previously, we reported sustained transgene expression of human iPSCs with REVec using a single iPSC line generated from primary dermal fibroblasts. To further investigate the efficiency of gene transfer into iPSCs derived from different somatic cell sources, seven human iPSC lines were plated on vitronectin coat as single cells and transduced with replication-defective REVec lacking the translation initiation codons for the glycoprotein gene at a MOI of 1.0. At 1 week post-transduction, expression of GFP and pluripotency marker SSEA4 was examined (Figure 1A). The percentage of GFP-positive cells ranged from 46.3% to 82% for bone-marrow-derived cells, 60.7% for cord-blood-derived cells, and ranged from 45.3% to 46% for fibroblast-derived cells (201B7 and 409B2). Expression of SSEA4 was confirmed in all transduced cells. To assess the cytotoxicity of REVec, cell viability was examined at 7 days post-transduction. As shown in Figure 1B, no significant change in cell viability was observed, indicating that REVec efficiently transduces iPSCs without appreciable cytotoxicity.

Comparison of iPSC Transduction Efficiency by Various Viral Vectors

To compare the efficiency of iPSC transduction by REVec and other commonly used viral vector platforms, iPSC lines BMI and BM9 were transduced with GFP-expressing AAV2 and adenovirus 5 (Ad5) vector at a MOI of 100 and with REVec, lentiviral, and Sendai virus (SeV) vector at a MOI of 10. The efficiency of gene delivery was determined at 1 and 2 weeks post-transduction by flow cytometry. At
1 week post-transduction, the percentage of GFP-positive cells was 69.3% for REVec, 49.9% for lentiviral vector, and 8.0% for SeV vector in BMI iPSCs (Figure 2A). The GFP-expressing cells were below the detection level in AAV2- and Ad5-vector-transduced cells. In BM9 iPSCs, the percentage of GFP-positive cells was highest with REVec (73.6%), followed by lentiviral vector (55.3%) and SeV vector (25.5%), and was below the detection limit for AAV2 and Ad5 vectors. To further examine the persistence of transgene expression, GFP-positive cell populations were next assessed at 2 weeks post-transduction (Figure 2B). Consistent with the result of 1 week, REVec achieved the highest efficiency of gene transfer into iPSCs.

**Differentiation Potentials of iPSCs Transduced with REVec and Lentiviral Vector**

Since REVec and lentiviral vectors achieved >50% GFP-positive cells, differentiation potentials of iPSCs transduced with these vectors were next examined by embryoid body (EB) formation assay. BMI and Epi iPSCs persistently transduced with REVec or lentiviral vector both formed EBs when cultured in DMEM containing 20% serum (Figure 3A). Immunocytochemistry for three embryonic-germ-layer-specific genes—including BRACHYURY (mesoderm), NESTIN (ectoderm), PAX6 (ectoderm), and SOX17 (endoderm)—revealed no notable difference in the expression of these genes in mock-, REVec-, and lentiviral-vector-transduced cells (Figure 3B). Interestingly, while strong GFP expression was achieved by REVec, loss of GFP expression was observed in lentiviral-vector-transduced cells upon spontaneous differentiation. To further quantify these results, qRT-PCR analysis was conducted and showed a decrease in expression of the pluripotency marker (OCT4) and an increase in expression of the mesoderm marker (BMP2), ectoderm marker (SOX1), and endoderm marker (SOX17) in EBs, compared to that in iPSCs (Figure 3C). Together, these results indicate that non-integrating REVec achieves efficient gene transfer into iPSCs and that transgene expression is maintained upon differentiation.

**Myogenic Differentiation of iPSCs Using REVec Encoding MyoD1**

To exploit REVec for in vitro genetic modification of iPSCs, we next sought to develop a vector to induce differentiation of iPSCs into somatic cells. In order to achieve this, we used myogenic
differentiation 1 (MyoD1), a transcription factor known as a master regulator of myogenesis, since overexpression of MyoD1 is sufficient to induce differentiation of iPSCs into skeletal muscle cells. Nonetheless, MyoD1 is not required once the cells are committed to myogenic lineage, thus providing us with a unique opportunity to test the small molecule inhibitor to switch off transgene expression from iPSC-derived cells. To generate REVec encoding MyoD1, we cloned MyoD1 cDNA from human rhabdomyosarcoma cell line TE671 in REVec vector plasmid containing GFP as a marker (Figure 4A). Vero cells stably expressing replication-competent

Figure 3. Differentiation Potentials of iPSCs Persistently Transduced with REVec and Lentiviral Vector
(A) Embryoid bodies (EBs) were generated from BMI and Epi iPSCs transduced with REVec and lentiviral vector by culturing in suspension in DMEM containing 20% FCS. Scale bars, 100 μm. (B) EBs were dissociated into smaller clumps, plated on Matrigel-coated chamber slides, and analyzed by immunostaining with BRACHYURY, NESTIN, PAX6, and SOX17 antibodies. Cells were counterstained with DAPI. Scale bars, 100 μm. (C) Transcript levels of OCT4, BMP2, SOX1, and SOX17 in iPSCs and EBs were determined by real-time RT-PCR. The relative expression levels were normalized to β-actin and reported as compared to mock iPSCs. Data are shown as averages of three independent experiments with error bars representing SEM.
REVec-MyoD1 GFP were generated by reverse genetics. The expression of MyoD1 and GFP was confirmed at 1 and 2 months post-transfection, indicating generation of stable REVec-producing cells (Figure 4B).

To induce differentiation of iPSCs into skeletal muscle cells, cell-free vector was prepared from vector-producing cells, and 201B7 and 409B2 iPSCs were transduced with GFP or MyoD1 GFP vector (Figure 4C). At 1 week post-transduction, spindle-shaped myocyte-like cells were observed in both cell lines transduced with MyoD1 vector at a MOI of 1.0. Infected cells were cultured for 1 week in iPSC medium, followed by incubation in DMEM containing 2% FCS to further induce formation of myotubes. (D) 201B7 and 409B2 iPSCs were transduced with REVec-GFP or REVec-MyoD1 GFP. At 1 week post-transduction, GFPGFP-positive cells were examined for differentiated morphology. Scale bars, 100 μm. (E) Differentiated cells after transfer to a plate without vitronectin coat. Scale bars, 100 μm. (F) Myogenic lineage of differentiated cells was assessed by immunostaining with MyoD1 and MHC antibodies. Scale bars, 50 μm. (G) Efficiency of myogenic differentiation by REVec. Ratio of MyoD1+/DAPI+ /DAPI+ cells and MHC+/DAPI+ /DAPI+ cells were determined and presented as percentage of MyoD1- and MHC-positive cells. Data are shown as averages of three independent experiments with error bars representing SEM. (H) One week after incubation in DMEM containing 2% FCS, multinucleated myotube formation was analyzed by immunostaining using MHC antibody and counterstaining with DAPI. Scale bars, 50 μm.
cells (Figure 4E) and analyzed for expression of myosin heavy chain markers, MyoD1, and myosin heavy chain (MHC) (Figure 4F). These cells were positive for MHC expression, indicating differentiation into the myogenic lineage. To further quantify the efficiency of differentiation, the percentages of MyoD1- and MHC-positive cells were determined from the ratios of MyoD1+DAPI+/DAPI+ cells and MHC+DAPI+/DAPI+ cells (Figure 4G). The percentage of MyoD1-positive cells was 73% for 201B7 and 76% for 409B2 iPSCs, while the percentage of MHC-positive cells was 73% for 201B7 and 62% for 409B2 cells.

During skeletal muscle development, mononucleated myoblasts fuse to form multinucleated myotubes. Therefore, differentiated cells were next cultured in DMEM supplemented with 2% FCS. After 1 week of incubation, multinucleated myotubes were generated (Figure 4H). Together, these results demonstrate the first example of an application of REVec for directed differentiation of iPSCs into a distinct cell lineage.

Shutoff of REVec from Persistently Transduced Cells with T-705
A strategy that can turn off transgene expression from persistently transduced cells is crucial not only for regulating gene expression but also for ensuring the safety of the viral vector. Previously, we reported that nucleoside/nucleotide mimetics favipiravir (T-705) exerts an antiviral activity against mammalian bornavirus BoDV-1 strain He/80 and avian bornavirus PaBV-4. To examine whether transgene expression can be switched off, iPSC-derived myocytes were treated with 50 and 400 μM T-705, and mRNA and genomic RNA (gRNA) levels of REVec were assessed by real-time RT-PCR (Figure 5A). At 14 days post-treatment, mRNA and gRNA levels were below the detection limit by real-time RT-PCR (Figure 5B). To further confirm the absence of REVec, T-705 was removed from the medium, and the cells were cultured for an additional 14 days. As shown in Figure 5C, mRNA and gRNA levels of REVec remained below the detection limit. Furthermore, GFP protein expression remained undetectable after the removal of T-705 from culture medium (Figure 5D). Together, these results indicate that T-705 treatment can be used to turn off transgene expression from persistently transduced stem-cell-derived cells.

DISCUSSION
In the present study, we investigated the feasibility of using REVec for the genetic modification of iPSCs. Our results indicate that various human iPSC lines are highly permissive to REVec. A side-by-side comparison with commonly used viral vectors demonstrated highly efficient and persistent gene transfer into iPSCs and iPSC-derived cells upon differentiation by the non-integrating REVec system. Moreover, we demonstrated the first example of in vitro application of REVec for genetic modification of iPSCs by inducing differentiation into skeletal muscle cells by MyoD1 transfer and further showed shutoff of transgene expression from persistently infected cells using T-705.

Genetic modification tools that efficiently mediate long-term stable gene expression in iPSCs while maintaining its pluripotency are invaluable for stem cell research. The delivery of transgenes to iPSCs has an advantage over gene transfer into differentiated cells, as iPSCs can provide an unlimited source of somatic cells. Rapti et al. previously compared iPSC transduction efficiency by recombinant AAV2, AAV6, Ad5, and lentiviral vectors and reported that lentiviral and Ad5 vectors exhibit higher transduction efficiency than AAV2 and AAV6 vectors. In our study, REVec and lentiviral vectors transduced iPSCs more efficiently than Ad5 vector. This discrepancy could be attributed to differences in the iPSC line and viral vector constructs used in the present study.
Among the selected vectors examined, we observed cytotoxicity in SeV vector-transduced cells, which was marked by changes in cell morphology (data not shown). Since BoDV particles are rarely released into the supernatant, REVec, in the present study, was prepared by sonication to release cell-associated vector. This results in a large amount of cell-derived impurities in the vector stock that could potentially reduce its efficacy and induce cytotoxicity, depending on the target cell type. Nevertheless, we did not observe cytotoxicity by REVec when used at a MOI of 1 to 10 in iPSCs, whereas cellular toxicity could be induced at a higher MOI. Thus, we are currently developing a REVec purification strategy to improve its safety and efficacy. Gene delivery with lentiviral vector involves integration in the host genome that comes with a risk for insertional mutagenesis and oncogenic transformation. Development of lentiviral vector with reduced genotoxicity has been achieved by the use of self-inactivating (SIN) vectors with a synthetic chromatin insulator cassette; however, due to the possibility of clonal expansion of infected cells, the risk of mutagenesis is not completely eliminated. Moreover, transgenes expressed by lentiviral vector are prone to silencing due to CpG methylation in the promoter region and histone deacetylation. In contrast to integrating systems, REVec is based on an RNA virus with no viral DNA phase and persists in the cell by interacting with host chromosomes as an episomal RNA. Therefore, REVec is not prone to transgene silencing by an epigenetic mechanism, and the risk of genotoxicity remains markedly lower than that for the aforementioned system.

The packaging capacity of the vector system can substantially affect its downstream applications. In this study, REVec expressing MyoD1 (963 bp) and GFP (720 bp) in tandem (combined transgene size, 1,683 bp) was successfully rescued by reverse genetics. Additionally, REVec encoding larger transgenes Neprilysin (2,253 bp) and LacZ (963 bp) and GFP (720 bp) in tandem (combined transgene size, 3,060 bp) has been generated in our previous studies. Further investigation is required to determine its maximum packaging capacity.

REVec particles are rarely released into the supernatant and remain highly associated with vector-producing cells. Moreover, due to its non-cytolytic nature, once stable REVec-producing cells are generated, they can be cultured for a long term for continuous vector production, as we have demonstrated in this study using Vero cells stably expressing MyoD1 and GFP. This presents an advantage over vector production by transient transfection method, as the stable vector-producing cells can be stored and expanded without the necessity to transfect cells prior to vector prep.

In this study, to demonstrate an application of REVec for genetic modification of iPSCs, a MyoD1-encoding vector was developed and used to induce differentiation of iPSCs into skeletal muscle cells. To date, various MyoD1 transfer systems have been used for the generation of skeletal muscle cells from iPSCs, including lentiviral vector expressing tamoxifen-inducible and doxycycline-inducible MyoD1, Ad5 expressing MyoD1, Tet-inducible MyoD1 piggyBac vector, and synthetic MyoD1 mRNA. In accordance with these studies, overexpression of MyoD1 by REVec generated MHC-positive myocytes. Although the purpose of this study was not to develop an efficient myogenic differentiation strategy, multinucleated myotubes were obtained in approximately 2 to 3 weeks using a two-step protocol, which was a relatively fast method compared to previously reported systems.

The ability to switch transgenes off from stably transduced cells is critical not only for controlling gene expression but also for limiting the potential adverse effects of therapy. However, currently, no strategy is available for removal of retroviral, lentiviral, and AAV vectors due to lack of antivirals and difficulty in eliminating integrated DNA. Remarkably, despite its ability to establish long-term persistence, REVec was eliminated with the clinically approved antiviral drug T-705. Recently, the persistent SeV vector, based on the noncytopathic persistent variant SeV Cl.151, was developed. Notably, Nishimura et al. demonstrated that SeV Cl.151 can be removed from persistently infected HeLa cells with small interfering RNAs (siRNAs) targeting viral genes. Thus, persistent episomal RNA vector systems that can be switched off by small molecule inhibitor or siRNA will further enhance the safety of these long-term gene expression systems.

In conclusion, the present study demonstrates REVec as an effective and safe system for genetic modification of iPSCs. Although further studies are required to increase vector purity and to assess its safety in vivo before translating this vector into clinical applications, REVec presents a promising gene transfer system for ex vivo iPSC-based gene therapy, with a unique fail-safe strategy with T-705.

MATERIALS AND METHODS

Cells and Chemicals

Vero cells were cultured in low-glucose DMEM (Nacalai Tesque, Kyoto, Japan) supplemented with 2% fetal calf serum (FCS). 293T cells were cultured in high-glucose DMEM (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FCS. Human iPSCs 110 (BYS0110), 112 (BYS0112), and 116 (BYS0116), were obtained from ATCC (Manassas, VA, USA). BMI and BM9 were obtained from WiCell (Madison, WI, USA). 201B7 and 409B2 were obtained from the Riken Biosource Center (Ibaraki, Japan). Epi was obtained from Thermo Fisher Scientific. Epi, BMI, BM9, 110, 112, and 116 were maintained on Corning Matrigel hESC-Qualified Matrix (CORNING, Corning, NY, USA) in mTeSR 1 medium (STEMCELL Technologies, Vancouver, BC, Canada). 201B7 and 409B2 were cultured on vitronectin (Thermo Fisher Scientific) in ReproFF2 medium (ReproCELL, Kanagawa, Japan) supplemented with 5 ng/mL basic fibroblast growth factor (bFGF; ReproCELL). T-705, Y27632, and puromycin were purchased from Selleckchem (Houston, TX, USA), FUJIFILM Wako Pure Chemical (Osaka, Japan), and InvivoGen (San Diego, CA, USA), respectively.

Viral Vectors

EGFP-expressing REVec, SeV vector, AAV2 vector, Ad5 vector, and HIV-SFFV-EGFP vector were described previously. To
generate replication-competent REVec expressing MyoD1 and EGFP. MyoD1 was PCR amplified from TE671 cells and inserted into the pFct-BoDV P/M-EGFP plasmid. Recombinant REVec was rescued by reverse genetics, as described previously.10 Briefly, 293T cells were co-transfected with pFct-BoDV P/M-MyoD1 EGFP and helper plasmids (N, P, and L) using Lipofectamine 2000 (Thermo Fisher Scientific) and overlaid with puromycin-resistant Vero cells. At 5 days post co-culture, cells were treated with puromycin and passaged until the majority of the cells became positive for vector production.

To determine the titers of EGFP-expressing lentiviral and SeV vectors, a total of 2 × 10^5 293T cells per well in 24-well plates were inoculated with serial dilutions of the vector supernatants overnight. Numbers of infected cells were determined by measurement of EGFP expression by fluorescence-activated cell sorting (FACS) using a FACScan and CELL QUEST software (Becton Dickinson, Franklin Lake, NJ, USA), and vector titers (infected units [IU] per milliliter) were estimated as follows: (2 × 10^5) × (% EGFP positive/100) × (1,000/microliters of infected viral vectors). The titers (genomic copy numbers per milliliter) of iodexanol-gradient-concentrated AAV and CsCl banding-purified adenoviral vector stocks were determined by real-time PCR using plasmid DNA standards and AAV genomic sequence-specific primers. The titer of REVec was determined by inoculating 2 × 10^4 293T cells seeded in a 96-well plate with serial dilutions of vector prep obtained by sonication of vector stocks. REVec was rescued by inoculating 2 × 10^4 infected viral vectors. The titers (genomic copy number per milliliter) of iodexanol-gradient-concentrated AAV and CsCl banding-purified adenoviral vector stocks were determined by real-time PCR using plasmid DNA standards and AAV genomic sequence-specific primers. The titer of REVec was determined by inoculating 2 × 10^4 293T cells seeded in a 96-well plate with serial dilutions of vector prep obtained by sonication of vector stocks. After absorption at 37°C for 2 h, the cells were washed and replaced with fresh medium and incubated for 72 h. Vector titer was determined by counting the number of EGFP-positive cells using a fluorescence microscope.

Transduction of iPSCs with REVec and Measurement of Cytotoxicity

iPSCs were dissociated into a single-cell suspension using ESGRO Complete Accutase (Merck Millipore, Burlington, MA, USA) and seeded in a 12-well plate at 0.3 × 10^4 cells per well. Rock inhibitor Y27632 was added at a final concentration of 10 μM. On the next day, cells were replaced with medium without Y27632 and inoculated with REVec at a MOI of 1.0 in a total volume of 200 μL. After absorption for 3 h at 37°C in a 5% CO2 incubator, supernatant containing the vector was replaced with fresh iPSC medium. The efficiency of iPSC transduction was determined by flow cytometry (BD Biosciences, San Jose, CA, USA) and the Tali Image-Based Cytometer (Thermo Fisher Scientific). The cytotoxicity of REVec was determined by WST-1 assay according to the manufacturer’s instructions (Takara Bio, Shiga, Japan).

Differentiation of iPSCs into Skeletal Muscle Cells

201B7 and 409B2 iPSCs were seeded in a vitronectin-coated 12-well plate at 0.3 × 10^4 cells per well and transduced with REVec-MyoD1 EGFP at a MOI of 1.0. At 1 week post-transduction, differentiated cells were transferred to a fresh 12-well plate without vitronectin coat and incubated in DMEM supplemented with 2% FCS for 1 week to induce formation of myotubes.

Immunostaining

The cells were fixed with 4% paraformaldehyde, permeabilized in 0.4% Triton-X, and blocked with PBS containing 2% BSA, followed by incubation with the following primary antibodies: BRACHYURY monoclonal antibody X1A02 (eBioscience, San Diego, CA, USA), Anti-SOX17 (R&D Systems, Minneapolis, MN, USA), PAX6 polyclonal antibody (Thermo Fisher Scientific), NESTIN monoclonal antibody 10C2 (Thermo Fisher Scientific), MyoD1 D8G3 (Cell Signaling Technology, Danvers, MA, USA), and anti-myosin heavy chain (R&D). After 1 h of incubation with primary antibody, cells were next washed with PBS and incubated with the following secondary antibodies: goat anti-rabbit IgG (immunoglobulin G) conjugated with Alexa Fluor 555, or goat anti-mouse IgG conjugated with Alexa Fluor 555, for 1 h at room temperature. Cells were next washed with PBS, and counterstained with DAPI. Secondary antibodies and DAPI were obtained from Thermo Fisher Scientific. Fluorescence images were taken with an Eclipse TE2000-U inverted microscope (Nikon, Shinagawa, Japan) or with a C1 confocal laser scanning system (Nikon).

EB Formation Assay

EBs were formed as previously described.12 Briefly, iPSCs were dissociated into single-cell suspension and cultured on low-adhesion plates in mTESR 1 medium for 4 days, followed by incubation in DMEM supplemented with 20% FCS for 1 week. For immunostaining, EBs were dissociated into smaller clumps and plated on Matrigel-coated chamber slides.

Real-Time RT-PCR

Total RNA was isolated from iPSCs and EBs using TRizol Reagent (Thermo Fisher Scientific), and cDNA was synthesized using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific), using oligo(dT)18 primer. qPCR analysis was performed using the Power SYBR Green PCR Master Mix (Applied Biosystems, Waltham, MA, USA) and analyzed on the StepOnePlus Real-Time PCR System (Applied Biosystems). The cycling conditions were as per the manufacturer’s instructions: 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The following primers were used: OCT4 (5'-gaaggttggctgctcaaggt-3' and 5'-gcttccaaatctctctg ttg-3'), BMP2 (5'-tgtgccgacacacaagc-3' and 5'-acaaccctcacaac atgt-3'), SOX1 (5'-ctgacaccactggttttt-3' and 5'-aagaacggctccctc tcc-3'), SOX17 (5'-atggcggagcgtatgatac-3' and 5'-ccatacaccggagt catgc-3'), and β-actin (5'-gcacatgtcactgaagta-3' and 5'-agttttcgccag atgttc-3'). The levels of REVec mRNA and gRNA were analyzed as described previously,10 using the following primers: oligo(dT) primer or BoDV-1 genome-specific primer (5'-tttgctgctaccaaaaaact ac-3') for cDNA synthesis and BoDV-1 P primers (5'-atcgtgaccaac ccgtta-3' and 5'-atcattcagctgtcccttc-3') for quantification of RNA.

AUTHOR CONTRIBUTIONS

Conceptualization, Y.K., D.T., and K.T.; Investigation, Y.K., D.T., and T.T.; Resources, Y.I., A.M., and H.S.; Writing – Original Draft, Y.K.;
Writing – Review & Editing, Y.K., K.T., Y.I., and T.H.; Supervision T.K.; Funding Acquisition, Y.K. and K.T.

CONFLICTS OF INTEREST
The authors declare no competing interests.

ACKNOWLEDGMENTS
We thank Jason M.T. and Claire A.S. at the Mayo Clinic for technical support and for preparing AAV2, Ad5, and lentiviral vectors. We thank Dr. Maria L. and Chantel R. at the Memorial University of Newfoundland for proofreading of the manuscript. This work was supported in part by a start-up grant (Y.K.) from The Keihanshin Consortium for Fostering the Next Generation of Global Leaders in Research (K-CONNEX); JSPS KAKENHI grant numbers JP18K18385 (to Y.K.) and JP17H04083 (to K.T.); MEXT KAKENHI grant numbers JP16H06429, JP16K21723, and JP16H06430 (to K.T.); MEXT Core-to-Core Program A; the Advanced Research Networks (to K.T.); and AMED grant numbers JP18am0301015 (to K.T.) and JP18fm020814 (to K.T.).

REFERENCES
1. Schambach, A., Zychlinski, D., Ehrstroem, B., and Baum, C. (2013). Biosafety features of lentiviral vectors. Hum. Gene Ther. 24, 132–142.
2. Thomas, C.E., Ehrhardt, A., and Kay, M.A. (2003). Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346–358.
3. Nakanishi, M., and Otsu, M. (2012). Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. Curr. Gene Ther. 12, 410–416.
4. Cox, D.B., Platt, R.J., and Zhang, F. (2015). Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131.
5. Ehrhardt, A., Haase, R., Schepers, A., Deutsch, M.J., Lipps, H.J., and Baiker, A. (2008). Episomal vectors for gene therapy. Curr. Gene Ther. 8, 147–161.
6. Ludwig, H., and Bode, L. (2000). Borna disease virus: new aspects on infection, disease and epidemiology. Rev. Sci. Tech. 19, 259–288.
7. Hans, A., Bajramovic, J.J., Syan, S., Perret, E., Dunia, I., Braic, M., and Gonzalez-Dunia, D. (2004). Persistent, noncytolytic infection of neurons by Borna disease virus interferes with ERK 1/2 signaling and abolishes BDNF-induced synaptogenesis. FASEB J. 18, 863–865.
8. Matsumoto, Y., Hayashi, Y., Omori, H., Honda, T., Daito, T., Horie, M., Ikuta, K., Fujino, K., Nakamura, S., Schneider, U., et al. (2012). Borna virus closely associates and segregates with host chromosomes to ensure persistent intranuclear infection. Cell Host Microbe 11, 492–503.
9. Horie, M., Kobayashi, Y., Suzuki, Y., and Tomonaga, K. (2013). Comprehensive analysis of endogenous bornavirus-like elements in eukaryote genomes. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368, 20120499.
10. Daito, T., Fuijno, K., Honda, T., Matsumoto, Y., Watanabe, Y., and Tomonaga, K. (2011). A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region. J. Virol. 85, 12170–12178.
11. Honda, T., Yamamoto, Y., Daito, T., Matsumoto, Y., Makino, A., and Tomonaga, K. (2016). Long-term expression of miRNA for RNA interference using a novel vector system based on a negative-strand RNA virus. Sci. Rep. 6, 26154.
12. Ikeeda, Y., Makino, A., Matchett, W.E., Holditch, S.J., Lu, B., Dietz, A.B., and Tomonaga, K. (2016). A novel intranuclear RNA vector system for long-term stem cell modification. Gene Ther. 23, 256–262.
13. Davis, R.L., Weintraub, H., and Lasar, A.B. (1987). Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987–1000.
14. Chal, J., and Pourquie, O. (2017). Making muscle: skeletal myogenesis in vivo and in vitro. Development 144, 2104–2122.
15. Goudeyne, S., Lebel, C., Huot, N.B., Dufour, C., Fujii, I., Gekas, J., Rousseau, J., and Tremblay, J.P. (2012). Myoblasts derived from normal ES cells and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation. Mol. Ther. 20, 2153–2167.
16. Tokunaga, T., Yamamoto, Y., Sakai, M., Tomonaga, K., and Honda, T. (2017). Antiviral activity of favipiravir (T-705) against mammalian and avian bornaviruses. Antiviral Res. 143, 237–245.
17. Rapti, K., Stillitano, F., Karakikes, I., Nonnenmacher, M., Weber, T., Hulot, J.S., and Hflajer, R.J. (2015). Effectiveness of gene delivery systems for pluripotent and differentiated cells. Mol. Ther. Methods Clin. Dev. 2, 14067.
18. Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Durso, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014). Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol. Ther. 22, 774–785.
19. Maldarelli, F., Wu, X., Xu, L., Simonetti, F.R., Shao, W., Hill, S., Spindler, J., Ferris, A.L., Mellors, J.W., Kearney, M.F., et al. (2014). Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183.
20. He, J., Yang, Q., and Chang, L.-J. (2005). Dynamic DNA methylation and histone modifications contribute to lentiviral transgene silencing in murine embryonic carcinoma cells. J. Virol. 79, 13497–13508.
21. Sakai, M., Ueda, S., Daito, T., Asada-Utsugi, M., Komatsu, Y., Kinoshita, A., Maki, T., Kuzuya, A., Takahashi, R., Makino, A., and Tomonaga, K. (2018). Degradation of amyloid β peptide by neprilysin expressed from Borna disease virus vector. Microbiol. Immunol. 62, 467–472.
22. Tedesco, F.S., Gerli, M.F.M., Perani, L., Benedetti, S., Ungaro, F., Cassano, M., Antonini, S., Tagliatela, E., Artusi, V., Longa, E., et al. (2012). Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci. Transl. Med. 4, 140ra89.
23. Abujouraj, R., Bennett, M., Valamehr, B., Lee, T.T., Robinson, M., Robbins, D., Le, T., Lai, K., and Flynn, P. (2014). Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery. Stem Cells Transl. Med. 3, 149–160.
24. Tanaka, A., Woljren, K., Miyake, K., Hotta, A., Ikeya, M., Yamamoto, T., Nishino, T., Shoji, E., Sehara-Fujisawa, A., Manabe, Y., et al. (2013). Efficient and reproducible myogenic differentiation from human iPSCs: prospects for modeling Miyoshi Myopathy in vitro. PloS ONE 8, e61540.
25. Nishimura, K., Segawa, H., Goto, T., Morishita, M., Masago, A., Takahashi, H., Ohmiya, Y., Sakaguchi, T., Asada, M., Imamura, T., et al. (2007). Persistent and stable gene expression by a cyttoplasmic RNA replicon based on a noncytopathic variant Sendai virus. J. Biol. Chem. 282, 27383–27391.
26. Nishimura, K., Sano, M., Ohtaka, M., Furuta, B., Umemura, Y., Nakajima, Y., Ikehara, Y., Kobayashi, T., Segawa, H., Takayasu, S., et al. (2011). Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J. Biol. Chem. 286, 4760–4771.
27. Kudva, Y.C., Ohmine, S., Greder, L.V., Dutton, J.R., Armstrong, A., De Lamo, I.G., Khan, Y.K., Thatava, T., Hasegawa, M., Fussak, N., et al. (2012). Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Transl. Med. 1, 451–461.
28. Schreiber, C.A., Sakuma, T., Izuimia, Y., Holditch, S.J., Hickey, R.D., Bressin, R.K., Basu, U., Koide, K., Asokan, A., and Ikeeda, Y. (2015). An siRNA screen identifies the U2 snRNP splicesome as a host restriction factor for recombinant adenovirus-associated viruses. PLoS Pathog. 11, e1005082.
29. Noser, J.A., Towers, G.J., Sakuma, R., Dumont, J.-M., Collins, M.K.L., and Ikeeda, Y. (2010). Development of retroviral and lentiviral vectors pseudotyped with xenotropic murine leukemia virus-related virus envelope glycoprotein. Hum. Gene Ther. 21, 1665–1673.